Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). *

 

Period Start 2002-01-01 established
Products Industry Viaskin® allergy treatment
  Industry 2 topical drug delivery technology
Persons Person Benhamou, Pierre-Henri (DBV Technologies 201508 CEO + Board Director of Biotech France)
  Person 2 Donne, Nathalie (DBV Technologies 201507 Director CorpComm + Business Development)
     
Region Region Bagneux, Hauts-de-Seine
  Country France
  Street 80/84 rue des Meuniers
  City 92220 Bagneux
  Tel +33-1-5542-7878
    Address record changed: 2018-07-24
     
Basic data Employees D: 101 to 500 (2017-12-31)
  Currency EUR
  Annual sales 11,909,000 (income, operating, consolidated (2017) 2017-12-31)
  Profit -147,693,000 (2016-12-31)
  Cash 137,880,000 (2017-12-31)
     
    * Document for �About Section�: DBV Technologies S.A.. (3/15/17). "Press Release: DBV Technologies Reports Full Year 2016 Financial Results".
     
   
Record changed: 2018-10-30

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top